The Food and Drug Administration Oct. 11 approved a new tablet for the acute treatment of migraine headache pain. Reyvow, or lasmiditan, is effective for migraine with or without aura, which appears as flashing lights or temporary loss of vision. While not meant as a preventive treatment, studies showed the tablet resolved pain and symptoms within two hours in many of the test patients. Migraine headaches affect one in seven Americans. “We know that the migraine community is keenly interested in additional treatment options,” said Nick Kozauer, M.D., acting deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “We remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine.”

Related News Articles

Headline
The AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical…
Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to…
Headline
The Food and Drug Administration yesterday approved the first test to use next generation sequencing technology to detect HIV drug-resistance mutations in…
Headline
Pictured, from left to right: Peter Adamson, chair of the Children’s Oncology Group at the Children’s Hospital of Philadelphia; Brian Marden, chief…
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe…